Progress Toward a Functional Cure for Chronic Hepatitis B: Current Research and Clinical Challenges

Researchers are making incremental progress toward a functional cure for chronic hepatitis B (CHB), a condition currently managed through long-term antiviral suppression rather than elimination of the virus. A functional cure is defined as the sustained suppression of the hepatitis B surface antigen (HBsAg) and undetectable HBV DNA in the blood after a finite course of therapy. According to the World Health Organization, approximately 254 million people live with chronic hepatitis B infection globally, necessitating more effective, short-term treatment options.

How Is Chronic Hepatitis B Currently Treated?

The standard of care for chronic hepatitis B involves long-term, often lifelong, therapy with nucleos(t)ide analogues (NAs) or pegylated interferon-alpha. NAs, such as entecavir and tenofovir, work by inhibiting the reverse transcriptase enzyme, preventing the virus from replicating. However, these drugs rarely lead to the clearance of the hepatitis B surface antigen. Because the virus integrates its DNA into the host’s genome, the Centers for Disease Control and Prevention (CDC) notes that current medications act as suppressive therapy rather than curative agents. Patients must remain on medication to prevent viral rebound.

What Are the Hurdles to Achieving a Functional Cure?

The primary barrier to a cure is the persistence of the covalently closed circular DNA (cccDNA) in the nuclei of infected liver cells. This viral DNA acts as a stable template for the production of new viral particles. Even when viral replication is suppressed by NAs, the cccDNA remains intact, allowing the virus to reactivate if treatment is interrupted. Recent clinical trials are exploring combination therapies that target different stages of the HBV life cycle, including entry inhibitors, capsid assembly modulators, and RNA interference (RNAi) agents designed to silence viral gene expression.

How Do New Therapeutic Approaches Differ?

Unlike traditional NAs that focus solely on inhibiting viral replication, emerging therapies aim to clear the virus through immune modulation or direct interference with viral components.

• RNA Interference (RNAi): Agents like bepirovirsen aim to reduce the levels of all HBV proteins by degrading viral mRNA.
• Entry Inhibitors: Drugs such as bulevirtide block the NTCP receptor, preventing the virus from entering healthy hepatocytes.
• Immune Modulators: These aim to boost the host’s immune system to recognize and eliminate infected cells, a process that is often “exhausted” in chronic patients.

According to the American Association for the Study of Liver Diseases (AASLD), while these novel agents have shown promise in Phase 2 clinical trials by achieving significant reductions in HBsAg, the challenge remains in demonstrating that these reductions lead to long-term, off-treatment clinical remission.

What Happens Next in Clinical Development?

The focus of future clinical research is shifting toward finite-duration combination regimens. Because no single drug has yet demonstrated the ability to eliminate cccDNA or achieve high rates of functional cure across diverse patient populations, researchers are testing whether combining direct-acting antivirals with immune-based therapies can trigger a sustained immune response. Regulatory bodies, including the U.S. Food and Drug Administration, continue to monitor these trials to determine if the safety profiles of multi-drug regimens are acceptable for long-term use in a population that is currently managed with well-tolerated, once-daily oral tablets.

Key Takeaways

• Chronic hepatitis B remains a global health challenge affecting over 250 million people.
• Current standard-of-care NAs effectively suppress replication but do not clear the virus.
• The persistence of cccDNA in liver cells is the primary obstacle to a permanent cure.
• Research is currently focused on combination therapies that combine viral suppression with immune system stimulation.